Venetoclax

證據等級: L5

預測適應症: 10 個

Venetoclax: From Established CLL/AML Indications to IGHV-Mutated CLL/SLL

One-Sentence Summary

Venetoclax is an orally administered BCL-2 inhibitor with internationally established use in chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). The TxGNN model’s top-ranked prediction for this candidate is IGHV-mutated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) — a molecularly defined subgroup within venetoclax’s existing disease class — with a prediction score of 99.55%, but this specific ranked entry returned no directly linked clinical trials or publications in the current evidence pack. Substantially more trial and literature support exists for other venetoclax entries in the same candidate bundle (Hodgkin’s/non-Hodgkin’s lymphoma, myeloid leukemia, CML blast phase).

Quick Overview

Item	Content
Original Indication	Not documented in this evidence pack (no Danish licenses on file). Based on established pharmacological knowledge, venetoclax’s internationally approved indications are CLL/SLL and AML.
Predicted New Indication	Chronic lymphocytic leukemia/small lymphocytic lymphoma with immunoglobulin heavy chain variable-region gene somatic hypermutation (IGHV-mutated CLL/SLL)
TxGNN Prediction Score	99.55%
Evidence Level	L5 (model prediction only — no clinical trials or literature directly linked to this ranked entry)
Denmark Market Status	Not marketed (未上市)
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in this evidence pack (flagged as a High-severity data gap). Based on established pharmacological knowledge, venetoclax is a selective, orally administered small-molecule inhibitor of BCL-2 (B-cell lymphoma 2), a protein that promotes malignant cell survival by blocking apoptosis. By binding BCL-2 and displacing pro-apoptotic proteins, venetoclax restores the intrinsic apoptotic pathway in malignant B-lymphocytes and myeloid blasts.

BCL-2 dependency is a shared biological feature across B-cell malignancies (CLL/SLL, Hodgkin’s and non-Hodgkin’s lymphomas) and myeloid malignancies (AML, CML blast phase), which is consistent with why this candidate bundle’s predictions converge broadly on hematologic malignancies. The specific top-ranked prediction — an IGHV-mutation-defined CLL/SLL subgroup — represents a molecular refinement within venetoclax’s already-established disease class rather than a mechanistically distant new indication.

Notably, although the top-ranked entry itself has no trials or publications indexed in this evidence pack, closely related entries within the same candidate bundle are extensively supported, including the pivotal MURANO trial (venetoclax-rituximab in relapsed/refractory CLL, PMID 40009494) and multiple completed Phase 3 studies in lymphoma and leukemia. This supports the general mechanistic plausibility of BCL-2 inhibition in this disease class, even though evidence specific to the IGHV-mutated subgroup was not separately retrieved by the searches recorded in this pack.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Denmark Market Information

Venetoclax is not currently marketed in Denmark; the Laegemiddelstyrelsen dataset in this evidence pack lists zero marketing authorisations for this drug.

Cytotoxicity

Venetoclax is an antineoplastic agent (BCL-2 inhibitor, indicated for leukemia/lymphoma), so this section applies.

Item	Content
Cytotoxicity Classification	Targeted therapy (selective BCL-2 inhibitor)
Myelosuppression Risk	Please refer to the Summary of Product Characteristics (SmPC) warnings and precautions
Emetogenicity Classification	Please refer to the Summary of Product Characteristics (SmPC) warnings and precautions
Monitoring Items	Please refer to the Summary of Product Characteristics (SmPC) warnings and precautions
Handling Protection	Please refer to the Summary of Product Characteristics (SmPC) warnings and precautions

Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Venetoclax is not marketed in Denmark (zero authorisations on file), a Blocking-severity data gap prevents any safety initial evaluation (TFDA/SmPC warnings and contraindications are missing), and the top-ranked predicted indication itself has no directly linked clinical trial or literature evidence in this pack (Evidence Level L5).

To proceed, the following is needed:

Obtain the official SmPC / product label (via EMA centralised procedure or manufacturer, since not yet authorised in Denmark) to close the blocking safety data gap
Confirm original approved indications and mechanism of action via DrugBank/EMA to close the MOA data gap
Run a targeted evidence search specific to the IGHV-mutated CLL/SLL molecular subgroup, since current searches returned zero trials/literature for this exact ranked entry
Consider evaluating the more evidence-rich related entries in this candidate bundle (venetoclax in Hodgkin’s/non-Hodgkin’s lymphoma combination regimens, myeloid leukemia, and CML blast phase), which show substantially stronger trial and literature support
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.